AbbVie Inc. ABBV
Set alert
At close · Oct 30
After hours · Oct 30, 6:40 PM ET
- YTD
- +29.06%
- 1 year
- +29.22%
- Open
- 292.00
- Prev close
- 290.79
- Mkt cap
- 521.11B
- Vol
- 6.90M
- Avg vol
- 4.72M
- EPS
- 3.54
- P/E
- 83.30
- Div yield
- 2.38%
More statistics
- Low
- 291.01
- High
- 298.74
- Forward P/E
- 18.15
- Beta
- 0.23
- Short ratio
- 3.22
- Inst. own
- 77.38%
- Dividend
- 6.92
- Ex-div date
- Oct 14, 2026
- Earnings
- Feb 3, 2027
- 50-d avg
- 268.63
- 200-d avg
- 236.73
- 1y target
- 283.19
5D chart
Events in this range
- Oct 30, 2026Earnings: 3.82; estimate 3.73; surprise 2.41%
Signals (149)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Oct 30, 3:45 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 3:45 PM | 2 days ago |
| SMA: Bearish | Oct 30, 3:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 3:30 PM | 2 days ago |
| SMA: Bearish | Oct 30, 2:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 2:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:40 PM | 2 days ago |
| SMA: Bearish | Oct 30, 1:35 PM | 2 days ago |
| SMA: Bullish | Oct 30, 1:00 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:50 PM | 2 days ago |
| MACD: Sell Signal | Oct 30, 12:50 PM | 2 days ago |
| MACD: Buy Signal | Oct 30, 12:45 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:15 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bearish | Oct 30, 12:10 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bullish | Oct 30, 12:05 PM | 2 days ago |
| SMA: Bearish | Oct 30, 11:45 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:40 AM | 2 days ago |
| SMA: Bullish | Oct 30, 11:35 AM | 2 days ago |
| SMA: Bearish | Oct 30, 11:30 AM | 2 days ago |
| SMA: Bullish | Oct 30, 10:50 AM | 2 days ago |
| MACD: Sell Signal | Oct 30, 10:20 AM | 2 days ago |
| SMA: Bearish | Oct 30, 10:15 AM | 2 days ago |
| RSI: Overbought | Oct 29, 3:55 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:45 PM | 3 days ago |
| RSI: Overbought | Oct 29, 3:35 PM | 3 days ago |
| SMA: Bullish | Oct 29, 3:10 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:40 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:30 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:25 PM | 3 days ago |
| SMA: Bearish | Oct 29, 2:15 PM | 3 days ago |
| SMA: Bullish | Oct 29, 2:00 PM | 3 days ago |
| MACD: Buy Signal | Oct 29, 1:55 PM | 3 days ago |
| SMA: Bullish | Oct 29, 1:45 PM | 3 days ago |
| SMA: Bearish | Oct 29, 12:30 PM | 3 days ago |
| SMA: Bullish | Oct 29, 12:20 PM | 3 days ago |
| SMA: Bearish | Oct 29, 11:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 11:15 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:45 AM | 3 days ago |
| SMA: Bullish | Oct 29, 10:40 AM | 3 days ago |
| MACD: Sell Signal | Oct 29, 10:30 AM | 3 days ago |
| SMA: Bearish | Oct 29, 10:15 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 29, 9:30 AM | 3 days ago |
| MACD: Buy Signal | Oct 29, 9:30 AM | 3 days ago |
| RSI: Overbought | Oct 29, 9:30 AM | 3 days ago |
| SMA: Bullish | Oct 28, 3:25 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:30 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 2:30 PM | 4 days ago |
| SMA: Bearish | Oct 28, 2:20 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:45 PM | 4 days ago |
| SMA: Bearish | Oct 28, 1:40 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:25 PM | 4 days ago |
| MACD: Buy Signal | Oct 28, 1:10 PM | 4 days ago |
| SMA: Bullish | Oct 28, 1:05 PM | 4 days ago |
| SMA: Bullish | Oct 28, 12:40 PM | 4 days ago |
| SMA: Bearish | Oct 28, 12:05 PM | 4 days ago |
| MACD: Sell Signal | Oct 28, 11:40 AM | 4 days ago |
| SMA: Bullish | Oct 28, 11:15 AM | 4 days ago |
| SMA: Bearish | Oct 28, 11:10 AM | 4 days ago |
| SMA: Bullish | Oct 28, 10:05 AM | 4 days ago |
| MACD: Buy Signal | Oct 28, 10:00 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:55 AM | 4 days ago |
| SMA: Bearish | Oct 28, 9:50 AM | 4 days ago |
| SMA: Bullish | Oct 28, 9:45 AM | 4 days ago |
| MACD: Sell Signal | Oct 28, 9:30 AM | 4 days ago |
| RSI: Oversold | Oct 28, 9:30 AM | 4 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:55 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:45 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:40 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:35 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bearish | Oct 27, 3:15 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 3:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:10 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 3:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 3:00 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bullish | Oct 27, 2:05 PM | 5 days ago |
| SMA: Bearish | Oct 27, 2:00 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:55 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 1:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 1:45 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 1:30 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bullish | Oct 27, 1:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:50 PM | 5 days ago |
| MACD: Sell Signal | Oct 27, 12:50 PM | 5 days ago |
| MACD: Buy Signal | Oct 27, 12:35 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:20 PM | 5 days ago |
| SMA: Bearish | Oct 27, 12:15 PM | 5 days ago |
| SMA: Bullish | Oct 27, 12:10 PM | 5 days ago |
| SMA: Bearish | Oct 27, 11:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 11:50 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 11:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 11:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:35 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:30 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:25 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:15 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bullish | Oct 27, 10:10 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bearish | Oct 27, 10:05 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:55 AM | 5 days ago |
| MACD: Buy Signal | Oct 27, 9:55 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:45 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bullish | Oct 27, 9:40 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bearish | Oct 27, 9:30 AM | 5 days ago |
| MACD: Sell Signal | Oct 27, 9:30 AM | 5 days ago |
| RSI: Oversold | Oct 27, 9:30 AM | 5 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 3:25 PM | 6 days ago |
| SMA: Bullish | Oct 26, 3:20 PM | 6 days ago |
| MACD: Buy Signal | Oct 26, 3:20 PM | 6 days ago |
| MACD: Sell Signal | Oct 26, 2:40 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bearish | Oct 26, 2:30 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:15 PM | 6 days ago |
| SMA: Bullish | Oct 26, 2:00 PM | 6 days ago |
| SMA: Bearish | Oct 26, 1:45 PM | 6 days ago |
| SMA: Bullish | Oct 26, 1:20 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:20 PM | 6 days ago |
| SMA: Bullish | Oct 26, 12:05 PM | 6 days ago |
| SMA: Bearish | Oct 26, 12:00 PM | 6 days ago |
| SMA: Bullish | Oct 26, 11:50 AM | 6 days ago |
| SMA: Bearish | Oct 26, 11:45 AM | 6 days ago |
| SMA: Bullish | Oct 26, 11:30 AM | 6 days ago |
News
1 day ago fool.com
AbbVie: 3 Key Takeaways for Long-Term Investors
AbbVie raised full-year net revenue guidance to $67.8 billion. Skyrizi and Rinvoq delivered $6 billion in combined growth this year.
1 day ago fool.com
Is AbbVie a Buy After Its Latest Earnings Report?
Adjusted EPS nearly doubled, but most of that comes from last year's big research-deal charge, and underlying growth was closer to 17%. Skyrizi and Rinvoq now account for nearly half of AbbVie's…
1 day ago seekingalpha.com
Dividend Champion, Contender, And Challenger Highlights: Week November 1
A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.
2 days ago seekingalpha.com
AbbVie Inc. (ABBV) Q3 2026 Earnings Call Transcript
AbbVie Inc. (ABBV) Q3 2026 Earnings Call Transcript
2 days ago marketbeat.com
What AbbVie (ABBV) Said on Its Q3 Earnings Call
AbbVie NYSE: ABBV reported third-quarter 2026 results above its guidance midpoint and raised its full-year revenue and adjusted earnings outlook, citing continued growth from its immunology and…
2 days ago benzinga.com
AbbVie Raises 2026 Outlook, Boosts Dividend
AbbVie hits a new 52-week high after beating Q3 2026 earnings estimates, raising its full-year guidance, and boosting its dividend.
2 days ago seekingalpha.com
AbbVie: Why I See More Upside After Q3
AbbVie Inc. reported strong third-quarter results. ABBV's revenue increased 10.3% YoY, while non-GAAP EPS rose 105.4%. Skyrizi, AbbVie's IL-23 antagonist, generated $5.78 billion in sales,…
2 days ago zacks.com
ABBV Beats on Q3 Earnings & Sales, Stock Rises on Raised '26 EPS View
AbbVie beats Q3 earnings and revenue estimates as strong immunology and neuroscience sales drive growth, prompting a higher 2026 EPS outlook.
2 days ago 247wallst.com
$250,000 in Merck, Pfizer, UnitedHealth and AbbVie Could Pay $8,000 a Year in Dividends
Dividends keep paying whether you sell or not, and four healthcare giants quietly generate serious retirement income while you sleep. But not every yield here is as safe as it looks.
2 days ago zacks.com
Here's What Key Metrics Tell Us About AbbVie (ABBV) Q3 Earnings
While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics…
2 days ago benzinga.com
Defensives Lead Sectors In Friday Trading As Growth Trails
Five sectors are higher and six are lower in Friday's regular session, with defensive sectors holding the top three positions. The leaders are clustered rather than separated, while Technology sits…
2 days ago 247wallst.com
CDs Offer Fixed Interest. AbbVie Offers a Growing Dividend.
AbbVie just handed shareholders their latest raise while your CD rate sits frozen, but the comparison between a guaranteed payment and a growing dividend gets complicated fast once taxes, price…
2 days ago benzinga.com
AbbVie Q3 2026 Earnings Call Transcript
AbbVie (NYSE:ABBV) reported third-quarter financial results on Friday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…
2 days ago zacks.com
AbbVie (ABBV) Tops Q3 Earnings and Revenue Estimates
AbbVie (ABBV) came out with quarterly earnings of $3.82 per share, beating the Zacks Consensus Estimate of $3.74 per share. This compares to earnings of $1.86 per share a year ago.
-
2 days ago benzinga.com
Conference call: AbbVie Raises FY2026 Sales Guidance from $67.600B to $67.800B vs $67.585B Est
AbbVie (NYSE:ABBV) raises FY2026 sales outlook from $67.600 billion to $67.800 billion vs $67.585 billion estimate.
-
2 days ago benzinga.com
Conference call: AbbVie Sees Q4 Adj EPS $3.83-$3.87 vs $3.89 Est; Sees Sales $18.400B vs $18.300B Est
AbbVie (NYSE:ABBV) is looking for Q4 Adj EPS of $3.83-$3.87 vs $3.89 analyst estimate. sees sales of $18.400 billion vs $18.300 billion analyst estimate.
2 days ago wsj.com
AbbVie Revenue Rises on Strength in Immunology, Neuroscience
The pharmaceutical company boosted its profit outlook for the year, and raised its quarterly dividend as both third-quarter results and full-year guidance came in above expectations.
-
2 days ago benzinga.com
AbbVie Q3 Adj. EPS $3.82 Beats $3.75 Estimate, Sales $17.404B Beat $17.314B Estimate
AbbVie (NYSE:ABBV) reported quarterly earnings of $3.82 per share which beat the analyst consensus estimate of $3.75 by 1.87 percent. This is a 105.38 percent increase over earnings of $1.86 per…
2 days ago prnewswire.com
AbbVie Reports Third-Quarter 2026 Financial Results
Reports Third-Quarter Diluted EPS of $2.37 on a GAAP Basis, an Increase of Over 100.0 Percent; Adjusted Diluted EPS of $3.82, an Increase of Over 100.0 Percent; These Results Include an Unfavorable…
2 days ago benzinga.com
Stock Market: Will S&P 500 Open Up or Down Today?
Will S&P 500 open higher? Polymarket odds plunge to 14% as Wall Street reacts to Alphabet's 10% drop, rising oil, and a broad tech selloff.
3 days ago benzinga.com
ExxonMobil, AbbVie On Deck Friday As Energy, Drug Growth Face Test
ExxonMobil headlines Friday’s reports, with investors watching whether strong energy production can sustain a sharp earnings recovery. AbbVie, Chevron, AstraZeneca, BP, Sanofi, General Dynamics,…
3 days ago 247wallst.com
AbbVie Stock: What 10 Years of Growth and Dividends Did for $1,000
AbbVie built its empire on a single blockbuster drug, then watched biosimilars gut it almost overnight.
3 days ago benzinga.com
8 Of 11 Sectors Rise Thursday As Defensives Lead
Eight sectors are higher and three are lower in Thursday’s regular session, with defensive sectors holding two of the top three positions. The leaders are separated rather than clustered, with Health…
3 days ago 247wallst.com
4 Reliable Dividend Stocks, Led by UPS, to Build Lifetime Passive Income
Wall Street spent years dismissing UPS as a broken dividend story, but a fresh earnings beat changed the conversation.
3 days ago benzinga.com
Steve Jobs' Son Says GLP-1 Weight Loss Drugs Could Be Among Most Important Medicines Ever, With Potential Impact on Cancer
Reed Jobs says GLP-1 drugs could help fight cancer; Yosemite fund passes $350M target.
-
3 days ago benzinga.com
AbbVie Announces Publication Of Results From Phase 3 TEMPLE Study In The Lancet Neurology; Study Results Showed Atogepant Outperformed Topiramate In Migraine Prevention
Phase 3 TEMPLE study evaluated the tolerability, safety and efficacy of atogepant (QULIPTA®) compared with topiramate for the preventive treatment of migraine in adults with a history of four or more…
3 days ago seekingalpha.com
Best Dividend Aristocrats For November 2026
Dividend Aristocrats underperformed SPY in September but rebounded sharply in October, narrowing the YTD gap. NOBL and the average Aristocrat have YTD returns of 13.13% and 13.35%, trailing SPY's…
4 days ago 247wallst.com
Why JEPI’s Total Return Has Outpaced Its Payout
JEPI's share price keeps climbing while its monthly cash payments quietly shrink, and the reason behind that split reveals something most income investors never check before buying a covered-call…
4 days ago prnewswire.com
The Countdown Is On: BOTOX® Cosmetic (onabotulinumtoxinA) Day is Back Nov. 18
The holiday celebrates personalized treatment with BOTOX® Cosmetic across four FDA-approved aesthetic indication areas, the one and only of its kind in the United States.1 BOTOX® Cosmetic Day marks…
4 days ago 247wallst.com
Retire on Dividends: 5 High-Yield Stocks Boomers Are Buying and Holding Forever
Treasury yields near 5% make dividend stocks work harder to justify their risk, yet five companies spanning tobacco, pipelines, telecom, pharma, and net-lease real estate have kept raising their…
5 days ago zacks.com
4 Arthritis Drug Stocks Investors Should Monitor for Growth Potential
LLY, NVS, JNJ and ABBV offer arthritis drug growth potential through rising sales, regulatory approvals and clinical advances across inflammatory joint diseases.
5 days ago zacks.com
Buy, Hold or Sell ABBV Stock? Key Tips Ahead of Q3 Earnings
AbbVie heads into Q3 earnings with growth from Skyrizi and Rinvoq, but rising expenses, declining estimates and intensifying competition raise near-term concerns.
5 days ago seekingalpha.com
AbbVie: Analyzing Performance, Pipeline, And Pricing Ahead Of Q3 (Strong Buy)
AbbVie Inc. is trading at all-time highs, with robust 2026 guidance and a market cap exceeding $500bn. I expect ABBV Q3 earnings to outperform, driven by immunology assets Skyrizi and Rinvoq, which…
5 days ago zacks.com
What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?
Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.
5 days ago prnewswire.com
Allergan Aesthetics Announces 2026 Grant Recipients of The Confidence Collective, Funded by BOTOX® Cosmetic (onabotulinumtoxinA)
Since its inception, The Confidence Collective has supported more than 500 women entrepreneurs and awarded more than $1.5 million in grants to fuel business growth and empower confidence. In 2026…
-
5 days ago benzinga.com
AbbVie Submits BLA To FDA For Etentamig, Second-Gen BCMA X CD3 Bispecific Antibody T-Cell Engager Administered Intravenously For Treatment Of Adults With Relapsed Or Refractory Multiple Myeloma
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of…
5 days ago prnewswire.com
AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma
– Etentamig is a second-generation BCMA-directed bispecific antibody T-cell engager with a clinical profile and dosing schedule that can potentially support treatment across a broad range of…
5 days ago defenseworld.net
AbbVie Inc. $ABBV Shares Sold by Hilton Head Capital Partners LLC
Hilton Head Capital Partners LLC cut its stake in AbbVie Inc. (NYSE: ABBV) by 63.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The…
5 days ago benzinga.com
Here's How Much $100 Invested In AbbVie 10 Years Ago Would Be Worth Today
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 3.9% on an annualized basis producing an average annual return of 17.65%. Currently, AbbVie has a market capitalization of…
6 days ago 247wallst.com
How Do You Tell a Yield Trap From a Real $6,400-a-Month Dividend Portfolio?
A 10% yield sounds like it solves the $6,400 monthly target with far less capital, but two of the three tests that expose a yield trap can disqualify a holding before you ever collect a check.
6 days ago prnewswire.com
Allergan Aesthetics Celebrates Eight Years of Engaging Girls in STEM Through Continued Partnership with Girls Inc.
Allergan Aesthetics and Girls Inc. continue their commitment to expanding mentorship, education and career exploration opportunities for girls nationwide. A STEM-focused workshop in San Antonio will…
6 days ago 247wallst.com
AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30
AbbVie (NYSE:ABBV | ABBV Price Prediction) reports third-quarter results before the open on October 30. Shares are up 28.55% year to date, and options pricing implies a roughly 5% move on the release.
6 days ago defenseworld.net
3,545 AbbVie Inc. $ABBV Shares Purchased by IRON Financial LLC
IRON Financial LLC raised its position in AbbVie Inc. (NYSE: ABBV) by 122.4% during the third quarter, according to its most recent filing with the SEC. The institutional investor owned 6,441 shares…
6 days ago seekingalpha.com
Best Dividend Kings: October 2026
Dividend Kings have outperformed SPY YTD, rising 13.5% versus SPY's 12.32%, with a strong October rebound. Twenty-six Dividend Kings appear both potentially undervalued and offer long-term annualized…
6 days ago fool.com
Billionaire Ken Griffin Is Buying This Dividend King That Wall Street Still Rates a Buy
Despite its high price relative to earnings, AbbVie remains an attractive stock.
1 week ago etftrends.com
A Worthwhile Exit Strategy
This week could mark something that hasn't happened to me in years—I may end up selling my shares of AbbVie (ABBV) at a price below the market value. It's all going to depend on if the share price…
1 week ago defenseworld.net
AbbVie Inc. $ABBV Stock: Evergreen Capital Management LLC Grows Stake
Evergreen Capital Management LLC lifted its position in shares of AbbVie Inc. (NYSE: ABBV) by 11.1% in the third quarter, according to the company in its most recent 13F filing with the Securities…
-
1 week ago benzinga.com
AbbVie Receives FDA Approval For Its Subcutaneous Induction Regimen For SKYRIZI To Treat Moderately To Severely Active Crohn's Disease
AbbVie (NYSE:ABBV) today announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for SKYRIZI® (risankizumab-rzaa) for adults with moderately to severely…
-
1 week ago benzinga.com
Goldman Sachs Maintains Neutral on AbbVie, Raises Price Target to $294
Goldman Sachs analyst Asad Haider maintains AbbVie (NYSE:ABBV) with a Neutral and raises the price target from $258 to $294.
1 week ago benzinga.com
What's Going On with MoonLake Immunotherapeutics Stock on Thursday?
MoonLake stock rallies after AbbVie HS data misses competitor benchmarks, reinforcing sonelokimab's competitive positioning ahead of 2027 launch plans.